Despite the uncertainty of how the Food and Drug Administration will regulate the use of CBD in food and other products, lawyers familiar with the industry say regulators will be interested in learning about labeling, concentration levels and the supply chain of CBD during the agency’s first public hearing on CBD in April.
Jennifer Fisher, a partner and team leader of the cannabis practice at Duane Morris in San Francisco, said regulators will likely want to know about things such as product testing and how the concentration of CBD will be controlled.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]